GAZAI
Phase 2 Unknown
89 enrolled
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Phase 2 Unknown
82 enrolled
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Phase 2 Unknown
40 enrolled
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Phase 2 Unknown
32 enrolled
FLMRD
Phase 2 Unknown
40 enrolled
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
Phase 2 Unknown
122 enrolled
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
Phase 2 Unknown
24 enrolled
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
Phase 2 Unknown
80 enrolled
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
Phase 2 Unknown
123 enrolled
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
Phase 2 Unknown
140 enrolled
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
Phase 2 Unknown
250 enrolled
ProT4
Phase 2 Unknown
114 enrolled
Human Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasia
Phase 2 Unknown
57 enrolled
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Phase 2 Unknown
38 enrolled
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
Phase 2 Unknown
21 enrolled
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Unknown
56 enrolled
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Phase 2 Unknown
52 enrolled
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
Phase 2 Unknown
70 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Unknown
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase 2 Unknown
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
Phase 2 Unknown
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Phase 2 Unknown
60 enrolled
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Phase 2 Unknown
60 enrolled
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
Phase 2 Unknown
30 enrolled
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Phase 2 Unknown
29 enrolled
Zevalin® First Line in Follicular Lymphoma
Phase 2 Unknown
60 enrolled
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
Phase 2 Unknown
30 enrolled
REAL07
Phase 2 Unknown
49 enrolled
FLIDVAX2006
Phase 2 Unknown
100 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Phase 2 Unknown
GOTEL-FL1LC
Phase 2 Unknown
38 enrolled
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
KLYMF
Phase 2 Unknown
45 enrolled